Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repeat Ivermectin Mass Drug Administrations for MALaria Control II (RIMDAMAL II): a Double-blind, Cluster-randomized Control Trial for Integrated Control of Malaria

NCT03967054 is registered in ClinicalTrials.gov with Brian Foy as lead sponsor.

NCT NCT03967054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03967054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repeat Ivermectin Mass Drug Administrations for MALaria Control II (RIMDAMAL II): a Double-blind, Cluster-randomized Control Trial for Integrated Control of Malaria
Lead sponsor
Brian Foy
Phase
Phase 3
Overall status
Completed
Start date
July 13, 2019
Completion date
August 1, 2024
Enrollment
4,124 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria